Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CYCLOPROPANAMINE COMPOUND AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2014/058071
Kind Code:
A1
Abstract:
The present invention provides a compound that: has a lysine-specific demethylase-1-inhibiting effect; and provides utility as a drug for preventing or treating schizophrenia, Alzheimer's disease, Parkinson's disease, and Huntington chorea. The present invention pertains to a compound expressed by formula (1) or salt thereof (where (A) represents a hydrocarbon group optionally having a substitution group or a heterocyclic group optionally having a substitution group; (B) represents a benzene ring optionally having a substitution group; (R1), (R2), and (R3) independently represent a hydrogen, a hydrocarbon group optionally having a substitution group, or a heterocyclic ring group optionally having a substitution group; (A) and (R1) can be bonded together to form, with an adjacent nitrogen atom, a cyclic group optionally having a substitution group; and (R2) and (R3) can be bonded together to form, with an adjacent hydrogen atom, a cyclic group optionally having a substitution group).

Inventors:
TOMITA NAOKI (JP)
TOMITA DAISUKE (JP)
TOMINARI YUSUKE (JP)
IMAMURA SHINICHI (JP)
MORIMOTO SHINJI (JP)
KOJIMA TAKUTO (JP)
TOYOFUKU MASASHI (JP)
HATTORI YASUSHI (JP)
KAKU TOMOHIRO (JP)
ITO MITSUHIRO (JP)
Application Number:
PCT/JP2013/077863
Publication Date:
April 17, 2014
Filing Date:
October 11, 2013
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
TAKEDA PHARMACEUTICAL (JP)
International Classes:
A61K31/166; C07C237/40; A61K31/167; A61K31/415; A61K31/4453; A61P25/14; A61P25/16; A61P25/28; A61P43/00; C07C237/30; C07C237/38; C07D231/40; C07D295/18; C12N9/99; C12N15/09
Domestic Patent References:
WO2010143582A12010-12-16
WO2010084160A12010-07-29
WO2010043721A12010-04-22
WO2011035941A12011-03-31
WO2011042217A12011-04-14
WO2012135113A22012-10-04
WO2012013728A12012-02-02
WO2011131697A12011-10-27
WO2012156531A22012-11-22
WO2012156537A22012-11-22
WO2013022047A12013-02-14
WO2013057320A12013-04-25
WO2010084160A12010-07-29
WO2010043721A12010-04-22
WO2011035941A12011-03-31
WO2011042217A12011-04-14
WO2010143582A12010-12-16
WO2012156531A22012-11-22
WO2012156537A22012-11-22
WO2012135113A22012-10-04
Foreign References:
JP2012036124A2012-02-23
US20100324147A12010-12-23
Other References:
BECKER ET AL., NATURE, vol. 442, 2006, pages 31 - 32
RUTHENBURG ET AL., NATURE REVIEWS MOLECULAR CELL BIOLOGY, vol. 8, 2007, pages 983 - 994
LEWITT ET AL., LANCET NEUROL., vol. 10, 2011, pages 309 - 319
CARLSON: "Physiology of Behavior", 2013
J. AM. CHEM. SOC., vol. 132, 2010, pages 6827 - 6833
THE JOURNAL OF NEUROSCIENCE, vol. 27, no. 42, 17 October 2007 (2007-10-17), pages 11254 - 11262
MOLECULAR AND CELLULAR BIOLOGY, vol. 31, no. 16, August 2011 (2011-08-01), pages 3298 - 3311
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Pharmaceutical Products", pages: 163 - 198
NATURE, vol. 447, 2007, pages 175
J. ORG. CHEM., vol. 76, 2011, pages 5061 - 5073
ORG. BIOMOL. CHEM., vol. 7, 2009, pages 2110 - 2119
J. MED. CHEM., vol. 52, 2009, pages 1885 - 1902
"Protective Groups in Organic Synthesis", 1980, JOHN WILEY AND SONS
BIOORG. MED. CHEM., vol. 19, 2011, pages 3709 - 3716
Attorney, Agent or Firm:
TAKASHIMA, HAJIME (JP)
Takashima 1 (JP)
Download PDF: